Keyphrases
Glioblastoma
100%
Bevacizumab
75%
Recurrent Glioblastoma multiforme
59%
Cetuximab
56%
Irinotecan
56%
Epidermal Growth Factor Receptor
37%
Glioblastoma multiforme
35%
Nivolumab
31%
Radiation Therapy
22%
Phase II Study
22%
Primary Glioblastoma
22%
Overall Survival
22%
Patient Selection
21%
Clinical Trials
20%
Checkpoint Pathway
18%
Temsirolimus
18%
Temozolomide
18%
Glioma Cells
18%
Multimodal Strategy
18%
Glioma
18%
Angiogenic Growth Factors
18%
Contrast Enhancement
18%
Targeted Therapy
18%
State Shift
18%
Prognostic Model
18%
Immune Response
18%
Tumor Cells
18%
Molecular Profiling
18%
Phase II Trial
18%
F-18
18%
Combination Therapy
18%
Diagnostic Performance
18%
Anaplastic Astrocytoma
18%
Downstream Signaling
18%
Brain Lesions
18%
Dynamic Contrast-enhanced Magnetic Resonance Imaging (DCE-MRI)
18%
Perfusion Measurement
18%
Blood Volume
18%
Recurrent Glioblastoma
18%
Single Institution
18%
Magnetic Resonance Perfusion
18%
Mesenchymal Tumor
18%
T Cell Activation
18%
Cell Growth
18%
Cell State
18%
Prospective Evaluation
18%
Positron Emission Tomography
18%
Tumor Tissue
17%
18F-fluoroethyl-L-tyrosine (18F-FET)
14%
Brain Tumor
13%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
97%
Cetuximab
56%
Bevacizumab
56%
Irinotecan
56%
Neoplasm
44%
Fluorine 18
37%
Epidermal Growth Factor Receptor
37%
Oligodendroglioma
18%
Temozolomide
18%
Biological Marker
18%
Phase II Trials
18%
Tyrosine
18%
Clinical Trial
7%
Hypoxia
7%
Brain Tumor
7%
Antiangiogenic
6%
Skin Toxicity
6%
Glioma
6%
Overall Survival
5%
Progression Free Survival
5%
Medicine and Dentistry
Glioblastoma
75%
Fluorine-18
37%
Overall Survival
21%
Ganglioglioma
21%
Magnetic Resonance Imaging
21%
Oligodendroglioma
18%
Targeted Therapy
18%
Positron Emission Tomography
18%
Nuclear Magnetic Resonance
18%
Diagnosis
18%
Cancer Treatment
18%
Tyrosine
18%
Mesenchymoma
18%
Positron Emission Tomography
18%
Drive
18%
Immunotherapy
18%
Immune Response
18%
Nivolumab
10%
Neoplasm
9%
Clinical Trial
8%
Tumor Cell
8%
Surgery
6%
Risk Stratification
5%
T Cell
5%